Top Pharmaceutical Companies in Singapore (56)
Biomed Global is a leading total solution provider in the biomedical and life sciences industry, operating across Southeast Asia. The company provides a holistic range of innovative medical solutions and cutting-edge biomedical technologies spanning research, development, and clinical applications. Its mission is to advance healthcare standards and facilitate medical breakthroughs by bringing together leading-edge medical solutions and expert support to...
Sustainability isn’t just about tackling climate change, it represents a growing conscience around our actions and the impact they have on people, animals and planet. The personal, professional and governmental move to sustainable practice is driven by a desire to change our impact on the world, but we can’t do this without knowing the certainty of our actions. Transparency...
Kyberlife's technology arm holds the first open marketplace in Asia with an easy-to-use platform that hosts healthcare vendors, life-science companies & manufacturers globally. Kyberlife also has a distribution arm that facilitates licensed distribution of life-science/pharmaceutical/medical products, Instruments, equipment to the SEA region. Our vision is to provide for the millions of researchers in Asia, SEA & Australasia to shop for...
Profound Change Requires Boldness. Johnson & Johnson is the largest and most broadly based healthcare company in the world. We’re producing life-changing breakthroughs every day, and have been for the last 130 years. The combination of new technologies and your expertise enables amazing things to happen. Teams from J&J’s consumer business are creating digital tools to help people track the...
Johnson & Johnson's Top Stability & Growth Strengths
Strong Revenue Growth: Companywide sales are described as increasing year over year, with momentum exiting 2025 and guidance calling for continued expansion into 2026.
Innovation-Driven Growth: Growth is attributed to innovative medicines and new product submissions, with oncology and immunology performance highlighted as key contributors.
Diversified Revenue Streams: The business is positioned around two large segments—Innovative Medicine and MedTech—creating a broader platform that helps offset declines in specific products.
reach52 is a Singapore-based healthtech social enterprise on a mission to redesign healthcare to reach the 52% of the world currently without access. They operate a fully integrated healthcare delivery model in emerging markets, leveraging community health educators and data-driven insights to provide affordable medicines, screening services, and health interventions through partnerships with governments, businesses, and social organizations.
EVERSANA is the provider of global services to the life science industry.
EVERSANA's Top Stability & Growth Strengths
Strong Market Position & Advantage: Evidence indicates EVERSANA maintains a strong market position through its integrated, end-to-end commercialization model and a top-tier agency network. Feedback suggests exclusive launch mandates and consistent MM+M top‑10 agency rankings reinforce this competitive advantage.
Innovation-Driven Growth: Feedback suggests the company is investing in AI-enabled and software-driven offerings, including an AI Accelerator, an AI-powered marketing agency, and Waltz Health’s drug-pricing/access technology. These moves position the platform for tech-enabled growth across access, pricing, and omnichannel execution.
Market Expansion: Evidence indicates EVERSANA is expanding capacity and reach through a large new distribution center and a merger that extends influence with payers and employers. Ongoing commercialization wins and partnerships show continued entry into adjacent access and pricing markets.
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing...
Novotech is a global full‑service clinical research organization (CRO) and scientific advisory partner that provides clinical trial execution, regulatory, laboratory and consulting services to biotech and small- to mid‑sized pharmaceutical companies. Operating across the Asia‑Pacific region and beyond with multiple offices and strategic site partnerships, Novotech helps sponsors accelerate development and access diverse patient populations for global drug development.
Vantive is a standalone vital organ therapy company dedicated to extending lives and expanding possibilities for patients and care teams globally. Building on a 70-year legacy in kidney care, Vantive provides innovative therapies, digital solutions, and advanced services for dialysis and critical care. The company operates in over 100 countries, focusing on improving outcomes for millions of patients through its...
With offices in Europe, North America and APAC, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools &...
Sinclair is a global medical aesthetics company that specializes in manufacturing and commercializing a wide portfolio of injectable and EBD treatments to support a consumer's full aesthetic journey. As a wholly owned subsidiary of Huadong Medicine Company Limited, the company's products are available in more than 55 countries through a direct presence in key global markets and a network of...
Sinclair's Top Stability & Growth Strengths
Strong Market Position & Advantage: Sinclair is positioned as a top-tier U.S. broadcaster with one of the largest station portfolios and owned networks that extend national reach. It is widely characterized as a leading player in local TV and sports content, even as Nexstar holds the top spot.
Strong Revenue Growth: Recent 2026 quarters show year-over-year revenue gains and higher full-year guidance, supported by stronger political demand, improving local media trends, and stable distribution. Digital-led core advertising is noted as a contributor to the uptick.
Innovation-Driven Growth: The company plays a leading role in ATSC 3.0/NextGen TV through ONE Media and continues to build specialty assets such as Tennis Channel. These initiatives broaden technology and content platforms that can diversify growth beyond legacy broadcast.
WonderLab is a non-profit organization providing pediatric physical, occupational, and speech therapy services.
AbbVie is a global biopharmaceutical company focused on creating medicines and solutions that put impact first — for patients, communities, and our world. We aim to address complex health issues and enhance people's lives through our core therapeutic areas: immunology, oncology, neuroscience, eye care, aesthetics and other areas of unmet need.
AbbVie's Top Stability & Growth Strengths
Strong Revenue Growth: Revenue reached a record ~$61.2B in 2025 and increased 10.2% year over year in Q2 2026, with adjusted EPS up 22.9%. Immunology and Neuroscience delivered double‑digit gains, led by Skyrizi and Rinvoq each growing about 24% in Q2 2026.
Strong Market Position & Advantage: AbbVie sits in the global top tier by sales and is a category leader in immunology and medical aesthetics. Skyrizi and Rinvoq are described as pace‑setters gaining share, while Allergan Aesthetics maintains leadership with Botox and fillers.
Diversified Revenue Streams: Multiple franchises contribute meaningfully—immunology, neuroscience (e.g., Vraylar, CGRPs), and aesthetics—supported by oncology additions like ELAHERE. Recent deals (Cerevel, ImmunoGen) and a broad late‑stage pipeline across oncology, neuroscience, and eye care expand the base.
SwipeRx, formerly mClinica, is the largest network of pharmacies in southeast Asia connecting over 235,000 pharmacy professionals from 45,000 pharmacies. SwipeRx pioneered the community-driven commerce model that unites the fragmented pharmacy channel on a single platform enabling them to access all the information, education and medicines they need. From online education, to centralized purchasing and logistics, to financing, SwipeRx caters...
IPS-Integrated Project Services, LLC, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities worldwide. With technical expertise spanning R&D to pilot-scale to large-scale production, our team specializes in the technology, trends, and regulatory environment to successfully deliver capital projects and improve...
The future of health is fast paced and complex, demanding a different approach. Established in 2001, our 1,300+ healthcare experts, combine their knowledge and expertise across our 4 core disciplines — Consulting; Medical; Marketing; and Policy, Access, Value, & Evidence. Working across the product and service lifecycle, from R&D to post launch, we engage our collective force to solve the complex...
Teva Pharmaceuticals has been developing and producing medicines to help improve people’s lives for more than a century. We are committed to being a global leader in generic and specialty medicines with a portfolio of 3,500 products in nearly every therapeutic area. Around 200 million people around the world take a Teva medicine every day. They are served by one...
At Lonza, we enable A Healthier World by supporting our healthcare customers on the path to commercialization. Our community of 16,000 talented employees work across a global network of more than 30 sites to deliver for our customers across the pharma, biotech and nutrition markets.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.
Novartis's Top Stability & Growth Strengths
Strong Revenue Growth: Novartis shows multi-year sales expansion, with full-year results indicating continued top-line growth driven by priority brands across several therapeutic areas.
Profitability: Margins and operating income are described as strengthening, with core operating margin reaching about 40% alongside year-over-year core operating income growth.
Innovation-Driven Growth: Growth is supported by scaling priority brands and a deep pipeline with multiple high-value assets, alongside business development to add late- and mid-stage programs.
We are Merck KGaA, Darmstadt, Germany and its global affiliates. We are a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and...
Merck KGaA, Darmstadt, Germany's Top Stability & Growth Strengths
Strong Market Position & Advantage: Merck KGaA is positioned as a leader in several defined niches, including infertility therapeutics, life-science bioprocessing/process solutions, and advanced semiconductor/display materials, with Electronics sharpened into a semiconductor-focused portfolio after the Surface Solutions divestment.
Profitability: The company is described as returning to profitable growth in 2024 and delivering on 2025 guidance, with EBITDA pre improving organically in both years despite foreign exchange headwinds.
Diversified Revenue Streams: The business mix across Life Science, Healthcare, and Electronics is framed as providing resilience, with segment-level growth contributors cited even when certain end markets faced cyclical or project-related softness.
